marketcaparena
Search

    AMPH

    Amphastar Pharmaceuticals, Inc.

    Company overview

    Market capitalization
    $1.17B
    Employees
    1,976
    Latest publication
    2026-09-29
    About Amphastar Pharmaceuticals, Inc.

    Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Total Revenue171,171,000USD183,105,000USD191,840,000USD174,414,000USD170,528,000USD186,523,000USD188,819,000USD182,394,000USD
    Cost Of Revenue100,849,000USD97,435,000USD93,194,000USD87,924,000USD85,277,000USD99,875,000USD86,878,000USD87,228,000USD
    Gross Profit70,322,000USD85,670,000USD98,646,000USD86,490,000USD85,251,000USD86,648,000USD101,941,000USD95,166,000USD
    Research Development26,737,000USD23,314,000USD22,354,000USD20,080,000USD20,096,000USD18,142,000USD21,077,000USD17,652,000USD
    Selling General Administrative18,028,000USD16,471,000USD39,467,000USD13,991,000USD15,996,000USD12,938,000USD14,821,000USD13,285,000USD
    Selling And Marketing Expenses11,927,000USD10,279,000USD11,505,000USD10,235,000USD11,866,000USD10,424,000USD8,995,000USD9,012,000USD
    Total Operating Expenses56,692,000USD50,064,000USD73,326,000USD44,306,000USD47,958,000USD41,504,000USD44,893,000USD39,949,000USD
    Operating Income13,630,000USD35,606,000USD25,320,000USD42,184,000USD37,293,000USD45,144,000USD57,048,000USD55,217,000USD
    Interest Income2,400,000USD2,423,000USD2,246,000USD1,921,000USD2,089,000USD2,292,000USD2,427,000USD3,337,000USD
    Interest Expense6,553,000USD6,630,000USD6,284,000USD6,281,000USD6,286,000USD6,425,000USD6,698,000USD8,609,000USD
    Net Interest Income-4,153,000USD-4,207,000USD-4,038,000USD-4,360,000USD-4,197,000USD-4,133,000USD-4,271,000USD-5,272,000USD
    Income Before Tax10,052,000USD31,914,000USD21,513,000USD39,335,000USD30,862,000USD43,962,000USD47,683,000USD50,243,000USD
    Income Tax Expense3,632,000USD7,485,000USD4,163,000USD8,305,000USD5,577,000USD5,998,000USD7,254,000USD12,294,000USD
    Tax Provision3,632,000USD7,485,000USD4,163,000USD8,305,000USD5,577,000USD5,998,000USD7,254,000USD12,294,000USD
    Net Income6,420,000USD24,429,000USD17,350,000USD31,030,000USD25,285,000USD37,964,000USD40,429,000USD37,949,000USD
    Net Income From Continuing Ops6,420,000USD24,429,000USD17,350,000USD31,030,000USD25,285,000USD37,964,000USD40,429,000USD37,949,000USD
    Ebit16,605,000USD38,544,000USD27,797,000USD45,616,000USD37,148,000USD50,387,000USD54,381,000USD58,852,000USD
    Ebitda33,097,000USD54,531,000USD41,926,000USD61,855,000USD52,355,000USD65,051,000USD68,814,000USD72,997,000USD
    Depreciation And Amortization16,492,000USD15,987,000USD14,129,000USD16,239,000USD15,207,000USD14,664,000USD14,433,000USD14,145,000USD
    Reconciled Depreciation16,492,000USD15,987,000USD15,768,000USD16,239,000USD15,207,000USD14,664,000USD14,433,000USD14,145,000USD
    Total Other Income Expense Net-3,578,000USD-3,692,000USD-3,807,000USD-2,849,000USD-6,431,000USD-1,182,000USD-9,365,000USD-4,974,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20202020-12-31 · USDFY 20162016-12-31 · USDFY 20132013-12-31 · USDFY 20122012-12-31 · USD
    Total Revenue719,887,000USD731,967,000USD644,395,000USD498,987,000USD349,846,000USD255,165,000USD229,681,000USD204,323,000USD
    Cost Of Revenue363,830,000USD358,112,000USD293,274,000USD250,127,000USD206,506,000USD150,976,000USD142,725,000USD114,020,000USD
    Gross Profit356,057,000USD373,855,000USD351,121,000USD248,860,000USD143,340,000USD104,189,000USD86,956,000USD90,303,000USD
    Research Development85,844,000USD73,914,000USD73,741,000USD74,771,000USD67,229,000USD41,199,000USD33,019,000USD31,163,000USD
    Selling General Administrative85,925,000USD56,720,000USD51,540,000USD45,061,000USD50,377,000USD41,832,000USD30,972,000USD27,223,000USD
    Selling And Marketing Expenses43,885,000USD37,802,000USD28,853,000USD21,531,000USD14,780,000USD5,466,000USD5,349,000USD4,426,000USD
    Total Operating Expenses215,654,000USD168,436,000USD154,134,000USD141,363,000USD132,386,000USD88,497,000USD69,340,000USD62,812,000USD
    Operating Income140,403,000USD205,419,000USD196,987,000USD107,497,000USD10,954,000USD15,692,000USD17,490,000USD25,397,000USD
    Interest Income8,679,000USD10,612,000USD3,736,000USD1,321,000USD642,000USD270,000USD——
    Interest Expense25,481,000USD30,343,000USD27,158,000USD1,846,000USD374,000USD1,024,000USD958,000USD784,000USD
    Net Interest Income-16,802,000USD-19,731,000USD-14,494,000USD-525,000USD268,000USD-754,000USD——
    Income Before Tax123,624,000USD189,191,000USD169,378,000USD114,863,000USD4,637,000USD14,946,000USD17,227,000USD25,878,000USD
    Income Tax Expense25,530,000USD29,672,000USD31,833,000USD23,477,000USD3,540,000USD4,414,000USD5,365,000USD7,784,000USD
    Tax Provision25,530,000USD29,672,000USD34,450,000USD23,477,000USD3,540,000USD4,414,000USD——
    Net Income98,094,000USD159,519,000USD137,545,000USD91,386,000USD1,403,000USD10,532,000USD11,862,000USD18,094,000USD
    Net Income From Continuing Ops98,094,000USD159,519,000USD135,291,000USD91,386,000USD1,097,000USD10,532,000USD——
    Ebit149,105,000USD220,107,000USD198,517,000USD117,886,000USD5,011,000USD15,692,000USD17,616,000USD26,662,000USD
    Ebitda212,306,000USD277,312,000USD240,294,000USD146,161,000USD30,191,000USD30,256,000USD30,694,000USD38,159,000USD
    Depreciation And Amortization63,201,000USD57,205,000USD41,777,000USD28,275,000USD25,180,000USD14,564,000USD13,078,000USD11,497,000USD
    Reconciled Depreciation63,201,000USD57,205,000USD35,780,000USD28,741,000USD25,180,000USD———
    Total Other Income Expense Net-16,779,000USD-16,228,000USD-27,609,000USD7,366,000USD-6,317,000USD-746,000USD-263,000USD-1,613,000USD
    Minority Interest——0USD0USD-306,000USD31,924,000USD——
    Non Operating Income Net Other———9,212,000USD-5,943,000USD278,000USD——
    Net Income Applicable To Common Shares———91,386,000USD1,403,000USD10,532,000USD11,862,000USD18,094,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Total Assets1,648,162,000USD1,629,299,000USD1,666,222,000USD1,615,333,000USD1,626,276,000USD1,577,470,000USD1,545,178,000USD1,491,522,000USD
    Intangible Assets556,293,000USD562,563,000USD568,833,000USD575,102,000USD581,371,000USD587,611,000USD591,540,000USD597,720,000USD
    Other Current Assets21,255,000USD32,754,000USD28,086,000USD22,763,000USD20,208,000USD20,649,000USD20,158,000USD10,380,000USD
    Total Liab874,771,000USD840,494,000USD889,476,000USD857,851,000USD874,993,000USD845,172,000USD817,500,000USD778,176,000USD
    Total Stockholder Equity773,391,000USD788,805,000USD776,746,000USD757,482,000USD751,283,000USD732,298,000USD727,678,000USD713,346,000USD
    Other Current Liab107,997,000USD98,828,000USD155,937,000USD124,671,000USD123,127,000USD126,543,000USD119,180,000USD99,437,000USD
    Common Stock6,000USD6,000USD6,000USD6,000USD6,000USD6,000USD6,000USD6,000USD
    Capital Stock6,000USD6,000USD6,000USD6,000USD6,000USD6,000USD6,000USD6,000USD
    Retained Earnings673,301,000USD666,881,000USD642,451,000USD625,102,000USD594,071,000USD568,787,000USD530,823,000USD490,394,000USD
    Good Will3,330,000USD3,402,000USD3,404,000USD3,397,000USD3,157,000USD3,049,000USD3,256,000USD3,129,000USD
    Cash171,174,000USD170,177,000USD216,500,000USD187,689,000USD182,782,000USD151,609,000USD192,116,000USD189,619,000USD
    Cash And Short Term Investments294,386,000USD282,812,000USD278,644,000USD231,751,000USD236,883,000USD221,645,000USD250,491,000USD217,775,000USD
    Total Current Assets633,683,000USD636,016,000USD639,470,000USD580,830,000USD587,961,000USD534,071,000USD545,949,000USD482,645,000USD
    Total Current Liabilities164,478,000USD158,156,000USD205,227,000USD176,407,000USD199,052,000USD173,759,000USD159,010,000USD136,971,000USD
    Net Debt515,204,000USD485,825,000USD440,273,000USD467,808,000USD469,751,000USD498,940,000USD437,732,000USD430,962,000USD
    Short Term Debt11,376,000USD9,569,000USD8,750,000USD8,806,000USD7,970,000USD7,038,000USD4,461,000USD4,245,000USD
    Short Long Term Debt1,671,000USD1,641,000USD923,000USD927,000USD224,000USD234,000USD252,000USD249,000USD
    Short Long Term Debt Total686,378,000USD656,002,000USD656,773,000USD655,497,000USD652,533,000USD650,549,000USD629,848,000USD620,581,000USD
    Long Term Debt609,801,000USD608,749,000USD608,582,000USD607,727,000USD603,858,000USD601,630,000USD596,446,000USD586,853,000USD
    Short Term Investments123,212,000USD112,635,000USD62,144,000USD44,062,000USD54,101,000USD70,036,000USD58,375,000USD28,156,000USD
    Net Receivables147,848,000USD143,560,000USD146,808,000USD134,585,000USD145,394,000USD138,036,000USD144,984,000USD132,079,000USD
    Inventory170,194,000USD176,890,000USD185,932,000USD191,731,000USD185,476,000USD153,741,000USD130,316,000USD122,411,000USD
    Accounts Payable35,500,000USD32,592,000USD40,540,000USD41,881,000USD52,813,000USD30,514,000USD34,088,000USD31,775,000USD
    Property Plant Equipment Net378,912,000USD353,719,000USD353,525,000USD354,734,000USD353,759,000USD344,627,000USD327,518,000USD320,572,000USD
    Property Plant Equipment Gross692,284,000USD659,985,000USD651,816,000USD645,215,000USD633,742,000USD616,214,000USD593,707,000USD578,754,000USD
    Accumulated Other Comprehensive Income-5,736,000USD-5,314,000USD-5,273,000USD-5,361,000USD-7,969,000USD-9,181,000USD-8,821,000USD-8,826,000USD
    Common Stock Shares Outstanding46,458,000shares47,164,000shares47,677,000shares48,128,000shares49,890,000shares52,058,000shares51,862,000shares52,046,000shares
    Non Current Assets Total1,014,479,000USD993,283,000USD1,026,752,000USD1,034,503,000USD1,038,315,000USD1,043,399,000USD999,229,000USD1,008,877,000USD
    Non Current Liabilities Total710,292,999USD682,338,000USD684,249,000USD681,444,000USD675,941,000USD671,413,000USD658,490,000USD641,205,000USD
    Non Current Liabilities Other29,365,000USD29,979,000USD29,269,000USD27,796,000USD24,421,000USD20,945,000USD27,037,000USD18,803,000USD
    Non Currrent Assets Other33,480,000USD31,135,000USD29,866,000USD28,099,000USD22,991,000USD25,992,000USD23,663,000USD24,260,000USD
    Net Working Capital469,205,000USD477,860,000USD434,243,000USD404,423,000USD388,909,000USD360,312,000USD386,939,000USD345,674,000USD
    Unclassified Non Current Assets42,464,000USD42,464,000USD71,124,000USD71,124,000USD71,124,000USD71,124,000USD53,252,000USD53,252,000USD
    Unclassified Current Liabilities7,934,000USD15,526,000USD——14,918,000USD9,430,000USD——
    Unclassified Non Current Liabilities71,126,999USD43,610,000USD46,398,000USD45,921,000USD47,662,000USD48,838,000USD35,007,000USD35,549,000USD
    Unclassified Equity105,814,000USD127,226,000USD139,556,000USD137,729,000USD165,169,000USD172,680,000USD205,664,000USD231,766,000USD
    Long Term Investments—0USD0USD2,047,000USD5,913,000USD10,996,000USD0USD9,944,000USD
    Current Deferred Revenue———————-3,996,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets1,629,299,000USD1,577,470,000USD1,512,912,000USD741,987,000USD671,529,000USD631,236,000USD586,971,000USD513,563,000USD
    Intangible Assets562,563,000USD587,611,000USD610,079,000USD34,172,000USD35,557,000USD36,675,000USD37,519,000USD38,316,000USD
    Other Current Assets32,754,000USD20,649,000USD11,492,000USD10,169,000USD9,835,000USD11,227,000USD9,849,000USD9,689,000USD
    Total Liab840,494,000USD845,172,000USD873,491,000USD213,329,000USD226,007,000USD182,513,000USD159,443,000USD149,204,000USD
    Total Stockholder Equity788,805,000USD732,298,000USD639,421,000USD528,658,000USD445,522,000USD402,306,000USD381,366,000USD332,435,000USD
    Other Current Liab98,828,000USD126,543,000USD194,018,000USD63,741,000USD67,331,000USD71,147,000USD51,990,001USD56,095,000USD
    Common Stock6,000USD6,000USD6,000USD6,000USD6,000USD5,000USD5,000USD5,000USD
    Capital Stock6,000USD6,000USD6,000USD6,000USD6,000USD5,000USD5,000USD5,000USD
    Retained Earnings666,881,000USD568,787,000USD409,268,000USD271,723,000USD180,337,000USD117,773,000USD116,370,000USD67,485,000USD
    Good Will3,402,000USD3,049,000USD3,216,000USD3,126,000USD3,313,000USD3,940,000USD3,634,000USD3,951,000USD
    Cash170,177,000USD151,609,000USD144,296,000USD156,098,000USD126,353,000USD92,642,000USD75,550,000USD86,337,000USD
    Cash And Short Term Investments282,812,000USD221,645,000USD256,806,000USD175,762,000USD136,673,000USD105,619,000USD89,515,000USD89,168,000USD
    Total Current Assets636,016,000USD534,071,000USD489,600,000USD378,319,000USD318,119,000USD279,682,000USD255,241,000USD220,342,000USD
    Total Current Liabilities158,156,000USD173,759,000USD225,407,000USD94,862,000USD103,810,000USD112,201,000USD90,009,000USD106,834,000USD
    Net Debt485,825,000USD498,940,000USD479,346,000USD-53,516,000USD-21,690,000USD-25,372,000USD-8,925,000USD-36,124,000USD
    Short Term Debt9,569,000USD7,038,000USD4,342,000USD6,049,000USD5,184,000USD15,620,000USD10,916,000USD18,229,000USD
    Short Long Term Debt1,641,000USD234,000USD436,000USD3,046,000USD2,202,000USD12,263,000USD7,741,000USD18,229,000USD
    Short Long Term Debt Total656,002,000USD650,549,000USD623,642,000USD102,582,000USD104,663,000USD67,270,000USD66,625,000USD50,213,000USD
    Long Term Debt608,749,000USD601,630,000USD589,579,000USD72,839,000USD74,776,000USD34,186,000USD39,394,000USD31,984,000USD
    Long Term Investments0USD10,996,000USD15,212,000USD2,414,000USD3,985,000USD0USD——
    Short Term Investments112,635,000USD70,036,000USD112,510,000USD19,664,000USD10,320,000USD12,977,000USD13,965,000USD2,831,000USD
    Net Receivables143,560,000USD138,036,000USD115,469,000USD88,804,000USD78,804,000USD66,005,000USD45,376,000USD52,163,000USD
    Inventory176,890,000USD153,741,000USD105,833,000USD103,584,000USD92,807,000USD96,831,000USD110,501,000USD69,322,000USD
    Accounts Payable32,592,000USD30,514,000USD25,438,000USD20,501,000USD22,214,000USD24,357,000USD25,061,000USD31,323,000USD
    Property Plant Equipment Net353,719,000USD344,627,000USD315,643,000USD264,573,000USD271,491,000USD280,709,000USD253,548,000USD210,418,000USD
    Property Plant Equipment Gross659,985,000USD616,214,000USD560,941,000USD264,573,000USD271,491,000USD280,709,000USD233,856,000USD210,418,000USD
    Accumulated Other Comprehensive Income-5,314,000USD-9,181,000USD-8,478,000USD-8,624,000USD-6,765,000USD-3,721,000USD-4,687,000USD-4,013,000USD
    Common Stock Shares Outstanding48,215,000shares52,058,000shares53,001,000shares52,427,000shares49,784,000shares49,124,000shares49,907,000shares46,395,000shares
    Non Current Assets Total993,283,000USD1,043,399,000USD1,023,312,000USD363,668,000USD353,410,000USD351,554,000USD331,730,000USD293,221,000USD
    Non Current Liabilities Total682,338,000USD671,413,000USD648,084,000USD118,467,000USD122,197,000USD70,312,000USD69,434,000USD42,370,000USD
    Non Current Liabilities Other29,979,000USD20,945,000USD22,718,000USD14,565,000USD46,887,000USD35,385,000USD29,173,000USD9,355,000USD
    Non Currrent Assets Other31,135,000USD25,992,000USD25,910,000USD20,856,000USD16,665,000USD5,250,000USD11,156,000USD9,918,000USD
    Net Working Capital477,860,000USD360,312,000USD264,193,000USD283,457,000USD214,309,000USD167,481,000USD165,232,000USD113,508,000USD
    Unclassified Non Current Assets42,464,000USD71,124,000USD53,252,000USD-20,856,000USD-16,665,000USD-25,904,000USD-11,156,000USD-9,918,000USD
    Unclassified Current Liabilities15,526,000USD9,430,000USD—1,525,000USD6,879,000USD-11,186,000USD-5,699,001USD-17,042,000USD
    Unclassified Non Current Liabilities43,610,000USD48,838,000USD35,787,000USD9,129,000USD-22,718,000USD-18,662,000USD-13,725,000USD-10,386,000USD
    Unclassified Equity127,226,000USD172,680,000USD238,619,000USD455,071,000USD422,417,000USD410,056,000USD367,300,000USD344,429,000USD
    Current Deferred Revenue——1,609,000USD————-56,095,000USD
    Other Liab———21,934,000USD22,718,000USD18,662,000USD13,725,000USD10,386,000USD
    Other Assets———59,383,000USD39,064,000USD50,884,000USD37,029,000USD40,536,000USD
    Treasury Stock———-189,524,000USD-150,479,000USD-121,812,000USD-97,627,000USD-75,476,000USD
    Net Tangible Assets———491,360,000USD406,652,000USD361,691,000USD340,213,000USD290,168,000USD
    Deferred Long Term Liab————534,000USD741,000USD867,000USD1,031,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income6,420,000USD24,429,000USD17,350,000USD31,030,000USD25,285,000USD37,964,000USD40,429,000USD37,949,000USD
    Depreciation14,348,000USD15,987,000USD14,129,000USD13,018,000USD15,207,000USD14,664,000USD-4,106,000USD14,145,000USD
    Stock Based Compensation9,274,000USD6,205,000USD6,297,000USD6,382,000USD8,393,000USD5,632,000USD5,596,000USD5,780,000USD
    Other Non Cash Items2,493,000USD28,971,000USD2,810,000USD3,687,000USD2,906,000USD-20,646,000USD25,370,000USD2,600,000USD
    Change To Account Receivables-4,547,000USD3,232,000USD-13,791,000USD12,267,000USD-8,075,000USD2,906,000USD-8,055,000USD6,679,000USD
    Change To Inventory6,248,000USD9,009,000USD5,860,000USD-4,821,000USD-31,111,000USD-24,468,000USD-7,309,000USD-7,025,000USD
    Change In Working Capital15,305,000USD-42,729,000USD11,997,000USD-18,525,000USD-16,714,000USD-8,590,000USD-7,327,000USD8,635,000USD
    Total Cash From Operating Activities47,840,000USD32,863,000USD52,583,000USD35,592,000USD35,077,000USD29,024,000USD59,962,000USD69,109,000USD
    Capital Expenditures-9,507,000USD-8,272,000USD-5,348,000USD-10,565,000USD-10,697,000USD-12,411,000USD-13,793,000USD-6,044,000USD
    Free Cash Flow38,333,000USD24,591,000USD47,235,000USD25,027,000USD24,380,000USD16,613,000USD46,169,000USD63,065,000USD
    Investments-7,226,000USD-51,863,000USD-19,619,000USD-625,000USD10,481,000USD-35,678,000USD-34,586,000USD-69,903,000USD
    Total Cashflows From Investing Activities-16,733,000USD-60,569,000USD-19,619,000USD-625,000USD10,481,000USD-35,678,000USD-34,586,000USD-69,903,000USD
    Net Borrowings-29,000USD169,000USD128,000USD4,092,000USD1,604,000USD4,753,000USD9,467,000USD—
    Total Cash From Financing Activities-30,207,000USD-18,373,000USD-4,347,000USD-30,202,000USD-14,503,000USD-33,842,000USD-22,816,000USD-10,716,000USD
    Sale Purchase Of Stock-29,492,000USD-20,516,000USD50,220,000USD-39,220,000USD-11,000,000USD-42,002,000USD-34,958,000USD-8,498,000USD
    Change In Cash762,000USD-46,088,000USD28,576,000USD4,907,000USD31,173,000USD-40,507,000USD2,497,000USD-11,529,000USD
    Begin Period Cash Flow170,412,000USD216,500,000USD187,924,000USD183,017,000USD151,844,000USD192,351,000USD189,854,000USD201,383,000USD
    End Period Cash Flow171,174,000USD170,412,000USD216,500,000USD187,924,000USD183,017,000USD151,844,000USD192,351,000USD189,854,000USD
    Other Cashflows From Investing Activities67,000USD-434,000USD-1,592,000USD-4,585,000USD-18,000USD-1,466,000USD-129,097,000USD-1,596,000USD
    Other Cashflows From Financing Activities-686,000USD5,728,000USD-54,197,000USD4,685,000USD-5,107,000USD3,407,000USD2,675,000USD1,000USD
    Unclassified Financing Cash Flow—-3,754,000USD—————-2,219,000USD
    Unclassified Investing Cash Flow——6,940,000USD15,150,000USD10,715,000USD13,877,000USD142,890,000USD7,640,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income98,094,000USD159,519,000USD137,545,000USD91,386,000USD63,301,000USD1,097,000USD46,505,000USD-6,660,000USD
    Depreciation63,201,000USD57,205,000USD41,777,000USD28,741,000USD26,752,000USD25,180,000USD21,121,000USD16,516,000USD
    Stock Based Compensation27,277,000USD24,368,000USD20,242,000USD17,860,000USD18,687,000USD20,498,000USD17,295,000USD16,680,000USD
    Other Non Cash Items5,886,000USD4,713,000USD21,885,000USD-878,000USD-13,031,000USD240,000USD1,036,000USD1,429,000USD
    Change To Account Receivables-6,367,000USD-21,671,000USD-26,086,000USD-10,132,000USD-14,921,000USD-20,160,000USD6,702,000USD-16,295,000USD
    Change To Inventory-21,063,000USD-48,797,000USD-1,724,000USD-11,746,000USD1,258,000USD15,297,000USD-41,103,000USD-5,984,000USD
    Change In Working Capital-65,971,000USD-14,547,000USD-24,209,000USD-32,177,000USD-1,924,000USD9,128,000USD-51,747,000USD12,104,000USD
    Total Cash From Operating Activities156,115,000USD213,386,000USD183,503,000USD89,181,000USD97,994,000USD57,266,000USD41,762,000USD38,191,000USD
    Capital Expenditures-34,882,000USD-41,041,000USD-38,166,000USD-24,034,000USD-27,456,000USD-33,855,000USD-41,555,000USD-46,808,000USD
    Free Cash Flow121,233,000USD172,345,000USD145,337,000USD65,147,000USD70,538,000USD23,411,000USD207,000USD-8,617,000USD
    Investments-28,839,000USD-124,930,000USD-546,296,000USD-7,792,000USD1,396,000USD-1,146,000USD-8,815,000USD-217,000USD
    Total Cashflows From Investing Activities-70,332,000USD-124,930,000USD-649,116,000USD-32,777,000USD-28,672,000USD-36,415,000USD-50,527,000USD-42,182,000USD
    Net Borrowings5,993,000USD10,170,000USD526,342,000USD-2,188,000USD30,361,000USD-880,000USD-3,211,000USD3,073,000USD
    Total Cash From Financing Activities-67,425,000USD-80,953,000USD454,093,000USD-26,439,000USD-37,018,000USD-2,246,000USD-3,783,000USD25,008,000USD
    Sale Purchase Of Stock-75,586,000USD-85,458,000USD-58,144,000USD-39,909,000USD-28,873,000USD-24,425,000USD-22,291,000USD-25,047,000USD
    Change In Cash18,568,000USD7,313,000USD-11,802,000USD29,745,000USD32,081,000USD18,957,000USD-12,652,000USD20,743,000USD
    Begin Period Cash Flow151,844,000USD144,531,000USD156,333,000USD126,588,000USD94,507,000USD75,550,000USD88,202,000USD67,459,000USD
    End Period Cash Flow170,412,000USD151,844,000USD144,531,000USD156,333,000USD126,588,000USD94,507,000USD75,550,000USD88,202,000USD
    Other Cashflows From Investing Activities-6,611,000USD-4,119,000USD1,390,000USD-1,372,000USD-2,612,000USD-1,414,000USD-157,000USD198,000USD
    Other Cashflows From Financing Activities-687,000USD-5,665,000USD-14,105,000USD15,251,000USD-40,244,000USD23,059,000USD3,421,000USD8,946,000USD
    Unclassified Operating Cash Flow27,628,000USD-17,872,000USD-13,737,000USD-15,751,000USD4,209,000USD1,123,000USD7,552,000USD-1,878,000USD
    Unclassified Financing Cash Flow2,855,000USD—454,093,000USD16,065,000USD17,663,000USD23,165,000USD18,298,000USD58,348,000USD
    Unclassified Investing Cash Flow—45,160,000USD-66,044,000USD————4,645,000USD
    Dividends Paid——-454,093,000USD-15,658,000USD-15,925,000USD-23,165,000USD—-20,312,000USD
    Change To Liabilities———-736,000USD3,016,000USD20,609,000USD-11,720,000USD29,159,000USD
    Cash And Cash Equivalents Changes———29,965,000USD32,304,000USD18,605,000USD-12,548,000USD20,743,000USD
    Issuance Of Capital Stock—————0USD18,298,000USD38,036,000USD
    Exchange Rate Changes———————-274,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2026Quarterly · 2026-03-31GeographyChina2,482,000USD0001297184-26-000033
    Q1 2026Quarterly · 2026-03-31GeographyFrance9,649,000USD0001297184-26-000033
    Q1 2026Quarterly · 2026-03-31GeographyUnited States159,040,000USD0001297184-26-000033
    Q4 2025Quarterly · 2025-12-31GeographyChina925,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31GeographyFrance10,629,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31GeographyUnited States171,551,000USDLegacy provider
    FY 2025Yearly · 2025-12-31GeographyChina3,184,000USD0001297184-26-000009
    FY 2025Yearly · 2025-12-31GeographyFrance35,281,000USD0001297184-26-000009
    FY 2025Yearly · 2025-12-31GeographyUnited States681,422,000USD0001297184-26-000009
    FY 2025Yearly · 2025-12-31ProductProduct719,887,000USD0001297184-26-000009
    FY 2025Yearly · 2025-12-31ProductResearch And Development Services3,200,000USD0001297184-26-000009
    Q3 2025Quarterly · 2025-09-30GeographyChina1,879,000USD0001297184-25-000064
    Q3 2025Quarterly · 2025-09-30GeographyFrance9,682,000USD0001297184-25-000064
    Q3 2025Quarterly · 2025-09-30GeographyUnited States180,279,000USD0001297184-25-000064
    Q3 2025Quarterly · 2025-09-30ProductPrimatenemist0USD0001297184-25-000064
    Q3 2025Quarterly · 2025-09-30ProductProduct191,840,000USD0001297184-25-000064
    Q3 2025Quarterly · 2025-09-30ProductResearch And Development Services1,900,000USD0001297184-25-000064
    Q2 2025Quarterly · 2025-06-30GeographyChina299,000USD0001297184-25-000050
    Q2 2025Quarterly · 2025-06-30GeographyFrance7,113,000USD0001297184-25-000050
    Q2 2025Quarterly · 2025-06-30GeographyUnited States167,002,000USD0001297184-25-000050
    Q2 2025Quarterly · 2025-06-30ProductProduct174,414,000USD0001297184-25-000050
    Q2 2025Quarterly · 2025-06-30ProductResearch And Development Services300,000USD0001297184-25-000050
    Q1 2025Quarterly · 2025-03-31GeographyChina81,000USD0001297184-26-000033
    Q1 2025Quarterly · 2025-03-31GeographyFrance7,857,000USD0001297184-26-000033
    Q1 2025Quarterly · 2025-03-31GeographyUnited States162,590,000USD0001297184-26-000033
    Q1 2025Quarterly · 2025-03-31ProductProduct170,528,000USD0001297184-25-000029
    Q1 2025Quarterly · 2025-03-31ProductResearch And Development Services100,000USD0001297184-25-000029
    Q4 2024Quarterly · 2024-12-31GeographyChina2,194,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31GeographyFrance9,239,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31GeographyUnited States175,090,000USDLegacy provider
    FY 2024Yearly · 2024-12-31GeographyChina4,339,000USD0001297184-26-000009
    FY 2024Yearly · 2024-12-31GeographyFrance19,947,000USD0001297184-26-000009
    FY 2024Yearly · 2024-12-31GeographyUnited States707,681,000USD0001297184-26-000009
    FY 2024Yearly · 2024-12-31ProductProduct712,814,000USD0001297184-26-000009
    FY 2024Yearly · 2024-12-31ProductProduct And Service Other19,153,000USD0001297184-26-000009
    FY 2024Yearly · 2024-12-31ProductResearch And Development Services4,200,000USD0001297184-26-000009
    Q4 2024Quarterly · 2024-12-31ProductProduct186,978,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductProduct And Service Other0USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductResearch And Development Services2,200,000USDLegacy provider
    Q3 2024Quarterly · 2024-09-30GeographyChina178,000USD0001297184-25-000064
    Q3 2024Quarterly · 2024-09-30GeographyFrance4,522,000USD0001297184-25-000064
    Q3 2024Quarterly · 2024-09-30GeographyUnited States186,514,000USD0001297184-25-000064
    Q3 2024Quarterly · 2024-09-30ProductProduct188,819,000USD0001297184-25-000064
    Q3 2024Quarterly · 2024-09-30ProductProduct And Service Other2,395,000USD0001297184-25-000064
    Q3 2024Quarterly · 2024-09-30ProductResearch And Development Services100,000USD0001297184-25-000064
    Q3 2024Quarterly · 2024-09-30SegmentActive Pharmaceutical Ingredient1,462,000USD0001297184-24-000058
    Q3 2024Quarterly · 2024-09-30SegmentFinished Pharmaceutical Products189,752,000USD0001297184-24-000058
    Q2 2024Quarterly · 2024-06-30GeographyChina1,564,000USD0001297184-25-000050
    Q2 2024Quarterly · 2024-06-30GeographyFrance4,410,000USD0001297184-25-000050
    Q2 2024Quarterly · 2024-06-30GeographyUnited States176,420,000USD0001297184-25-000050
    Q2 2024Quarterly · 2024-06-30ProductProduct179,388,000USD0001297184-25-000050
    Q2 2024Quarterly · 2024-06-30ProductProduct And Service Other3,006,000USD0001297184-25-000050
    Q2 2024Quarterly · 2024-06-30ProductResearch And Development Services1,500,000USD0001297184-25-000050
    Q2 2024Quarterly · 2024-06-30SegmentActive Pharmaceutical Ingredient3,535,000USD0001297184-24-000048
    Q2 2024Quarterly · 2024-06-30SegmentFinished Pharmaceutical Products178,859,000USD0001297184-24-000048
    Q1 2024Quarterly · 2024-03-31ProductActive Pharmaceutical Ingredient1,692,000USD0001297184-24-000037
    Q1 2024Quarterly · 2024-03-31ProductBaqsimi13,843,000USD0001297184-24-000037
    Q1 2024Quarterly · 2024-03-31ProductBaqsimi Neb14,207,000USD0001297184-24-000037
    Q1 2024Quarterly · 2024-03-31ProductEnoxaparin7,096,000USD0001297184-24-000037
    Q1 2024Quarterly · 2024-03-31ProductEpinephrine26,110,000USD0001297184-24-000037
    Q1 2024Quarterly · 2024-03-31ProductGlucagon28,535,000USD0001297184-24-000037
    Q1 2024Quarterly · 2024-03-31ProductLidocaine12,773,000USD0001297184-24-000037
    Q1 2024Quarterly · 2024-03-31ProductNaloxone4,287,000USD0001297184-24-000037
    Q1 2024Quarterly · 2024-03-31ProductOther Product Revenues Net29,154,000USD0001297184-24-000037
    Q1 2024Quarterly · 2024-03-31ProductPhytonadione9,973,000USD0001297184-24-000037
    Q1 2024Quarterly · 2024-03-31ProductPrimatenemist24,166,000USD0001297184-24-000037
    Q1 2024Quarterly · 2024-03-31ProductResearch And Development Services400,000USD0001297184-24-000037
    Q1 2024Quarterly · 2024-03-31SegmentActive Pharmaceutical Ingredient1,692,000USD0001297184-24-000037
    Q1 2024Quarterly · 2024-03-31SegmentFinished Pharmaceutical Products170,144,000USD0001297184-24-000037
    FY 2023Yearly · 2023-12-31GeographyChina4,505,000USD0001297184-26-000009
    FY 2023Yearly · 2023-12-31GeographyFrance4,698,000USD0001297184-26-000009
    FY 2023Yearly · 2023-12-31GeographyUnited States635,192,000USD0001297184-26-000009
    FY 2023Yearly · 2023-12-31ProductProduct593,238,000USD0001297184-26-000009
    FY 2023Yearly · 2023-12-31ProductProduct And Service Other51,157,000USD0001297184-26-000009
    FY 2023Yearly · 2023-12-31ProductResearch And Development Services4,500,000USD0001297184-26-000009
    Q4 2023Quarterly · 2023-12-31SegmentActive Pharmaceutical Ingredient3,074,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31SegmentFinished Pharmaceutical Products175,031,000USDLegacy provider
    FY 2023Yearly · 2023-12-31SegmentActive Pharmaceutical Ingredient14,122,000USD0001297184-24-000009
    FY 2023Yearly · 2023-12-31SegmentFinished Pharmaceutical Products630,273,000USD0001297184-24-000009
    Q3 2023Quarterly · 2023-09-30ProductProduct151,855,000USD0001297184-24-000058
    Q3 2023Quarterly · 2023-09-30ProductProduct And Service Other28,701,000USD0001297184-24-000058
    Q3 2023Quarterly · 2023-09-30ProductResearch And Development Services800,000USD0001297184-24-000058
    Q3 2023Quarterly · 2023-09-30SegmentActive Pharmaceutical Ingredient4,190,000USD0001297184-24-000058
    Q3 2023Quarterly · 2023-09-30SegmentFinished Pharmaceutical Products176,366,000USD0001297184-24-000058
    Q2 2023Quarterly · 2023-06-30SegmentActive Pharmaceutical Ingredient2,846,000USD0001297184-24-000048
    Q2 2023Quarterly · 2023-06-30SegmentFinished Pharmaceutical Products142,866,000USD0001297184-24-000048
    Q1 2023Quarterly · 2023-03-31SegmentActive Pharmaceutical Ingredient4,012,000USD0001297184-24-000037
    Q1 2023Quarterly · 2023-03-31SegmentFinished Pharmaceutical Products136,010,000USD0001297184-24-000037
    FY 2022Yearly · 2022-12-31GeographyChina4,697,000USD0001297184-25-000008
    FY 2022Yearly · 2022-12-31GeographyFrance7,457,000USD0001297184-25-000008
    FY 2022Yearly · 2022-12-31GeographyUnited States486,833,000USD0001297184-25-000008
    FY 2022Yearly · 2022-12-31ProductProduct498,987,000USD0001297184-25-000008
    FY 2022Yearly · 2022-12-31ProductResearch And Development Services4,300,000USD0001297184-25-000008
    Q4 2022Quarterly · 2022-12-31SegmentActive Pharmaceutical Ingredient2,307,000USDLegacy provider
    Q4 2022Quarterly · 2022-12-31SegmentFinished Pharmaceutical Products132,716,000USDLegacy provider
    FY 2022Yearly · 2022-12-31SegmentActive Pharmaceutical Ingredient12,482,000USD0001297184-24-000009
    FY 2022Yearly · 2022-12-31SegmentFinished Pharmaceutical Products486,505,000USD0001297184-24-000009
    FY 2021Yearly · 2021-12-31GeographyChina6,020,000USD0001297184-24-000009
    FY 2021Yearly · 2021-12-31GeographyFrance11,879,000USD0001297184-24-000009
    FY 2021Yearly · 2021-12-31GeographyUnited States419,869,000USD0001297184-24-000009

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.